Pivotal Response Treatment for Infants At-Risk for Autism Spectrum Disorder
|ClinicalTrials.gov Identifier: NCT01691066|
Recruitment Status : Unknown
Verified July 2015 by Yale University.
Recruitment status was: Active, not recruiting
First Posted : September 24, 2012
Last Update Posted : July 2, 2015
|Condition or disease||Intervention/treatment|
|Autism Spectrum Disorders||Behavioral: Infant Toddler Years PRT|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Pivotal Response Treatment for Infants At-Risk for Autism Spectrum Disorder|
|Study Start Date :||September 2012|
|Primary Completion Date :||September 2014|
|Estimated Study Completion Date :||September 2015|
Experimental: Infant Toddler Years PRT
Infant Toddler PRT in an evidence-based, manualized treatment for children with autism spectrum disorder that involves specific motivational behavioral procedures adapted to be developmentally appropriate for 12-15 month old infants who present with developmental delays.
Behavioral: Infant Toddler Years PRT
Other Name: Pivotal Response Treatment
No Intervention: Community Treatment
Community Treatment includes the treatments offered by early intervention services (e.g., speech-language therapy, special education instruction).
- Feasibility of a novel behavioral treatment [ Time Frame: 24 months ]
Assessment of Outcome:
Attendance. Attendance to parent education sessions will be recorded by the therapist.
Parent utilization. To assess the acceptability of the PRT approach, parents will be asked to keep a weekly log of procedure use, including overall estimated duration and choice of activities.
- Acceptability of a novel behavioral treatment [ Time Frame: 24 months ]
Assessment of Outcome:
Parent satisfaction. At post-treatment, parents will be asked to complete a Likert-scale and short response questionnaire rating their satisfaction with various aspects of the program
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01691066
|United States, Connecticut|
|Yale Child Study Center|
|New Haven, Connecticut, United States, 06510|
|Principal Investigator:||Katarzyna Chawarska, PhD||Yale University|